%0 Journal Article
%T 肺腺癌脑转移患者EGFR-TKI耐药后治疗的文献综述<br>A Literature Review on the Treatment of Patients with Brain Metastasis from Lung Adenocarcinoma after EGFR-TKI Resistance
%A 刘雨欣
%A 李长毅
%J Advances in Clinical Medicine
%P 3235-3241
%@ 2161-8720
%D 2025
%I Hans Publishing
%R 10.12677/acm.2025.1541291
%X 驱动基因阳性肺腺癌患者口服靶向药物较传统化疗 + 免疫治疗相比&#65292;病人有更好的依从性&#65292;治疗效果更佳。然而国内外多项研究显示&#65292;药物耐药性不可规避。多种耐药机制使得少部分患者初始使用EGFR-TKIs时即对药物不敏感&#65292;或肿瘤在3个月内迅速进展&#65292;敏感患者长时间口服药物后也会出现耐药现象。因此耐药后治疗方案的选择对于患者预后十分重要。本文将收录的近15年国内外有关肺腺癌脑转移靶向药物耐药后治疗方案选择的文献总结&#65292;能给患者带来更好预后的治疗方案。<br>Compared with traditional chemotherapy and immunotherapy, patients with positive driver gene lung adenocarcinoma who take targeted drugs have better compliance and better therapeutic effect. However, many studies at home and abroad have shown that drug resistance is inevitable. Multiple resistance mechanisms cause that a small number of patients are insensitive to the drugs when they initially use EGFR-TKIs, or the tumor progresses rapidly within 3 months. Even sensitive patients may develop drug resistance after long-term oral administration of drugs. Therefore, the choice of treatment plan after drug resistance is very important for the prognosis of patients. This article summarizes the literature on the selection of treatment plans for targeted drugs for lung adenocarcinoma with brain metastasis in the past 15 years from both domestic and foreign sources, which can provide patients with better treatment plans for better prognosis.
%K EGFR-TKI耐药&#65292
%K 肺腺癌&#65292
%K 脑转移<br>EGFR-TKI Drug Resistant
%K Lung Adenocarcinoma
%K Brain Metastasis
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=113007